Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025
28 Oktober 2024 - 1:30PM
Biogen Inc. (Nasdaq: BIIB) today announced that Michael McDonnell,
Biogen’s Executive Vice President and Chief Financial Officer,
plans to retire from the company on February 28, 2025. Upon Mr.
McDonnell’s retirement, Robin Kramer, currently Chief Accounting
Officer at Biogen, will assume the role of Chief Financial Officer
(CFO). In the coming weeks and months, Mr. McDonnell will work
closely with Ms. Kramer to ensure a smooth transition.
Mr. McDonnell, who has served in his current role since August
2020, has been instrumental to repositioning Biogen towards the
goal of returning to sustainable growth. He notably led a program
to re-align the company’s cost structure to its revenue base and to
redeploy capital in areas of potential growth. As part of these
efforts, Mr. McDonnell played a pivotal role in recent strategic
acquisitions of late-stage assets and in creating a culture of
financial discipline and continuous improvement across the
company.
“On behalf of the Board of Directors and our entire leadership
team, I would like to extend our gratitude to Mike for his years of
dedication to Biogen. In the two years we have worked
together, Mike has demonstrated strong leadership during our Fit
for Growth program, and he has been an important and valued counsel
for me and our team,” said Christopher A. Viehbacher, Biogen
President and Chief Executive Officer.
“Mike leads a strong team, and I am pleased to be able to
announce that Robin Kramer will succeed Mike as Executive Vice
President and CFO when Mike retires early next year. Her deep
understanding of our business, coupled with her breadth of
knowledge and leadership experience give me great confidence in her
as our next CFO,” Viehbacher continued. “Robin will join the
Executive Committee and work with our leadership team to build
upon Biogen’s transformation and further advance our strategic
vision.”
Ms. Kramer joined Biogen in 2018 and has served as Senior Vice
President and Chief Accounting Officer since 2020. In this
capacity, she has overseen key finance functions including
Treasury. She is also responsible for global procurement and
Biogen's Global Business Services operations. She brings a strong
track record of corporate financial and accounting experience
across different industries, including biotechnology, and will
continue to be a key contributor to the advancement of Biogen’s
sustained performance. She has partnered with Mr. McDonnell and the
rest of the leadership team on the company’s M&A strategy and
other strategic growth initiatives. Ms. Kramer works closely with
the Board of Directors and the Audit Committee.
“I am honored to assume the role of CFO as Biogen continues to
execute on its strategic transformation for the benefit of our
patients, partners, employees and shareholders,” said Ms. Kramer.
“Mike has been a wonderful mentor to me the last few years, and I
look forward to working with Chris, the Executive Committee and the
Board as we continue to advance and deliver on the strategic and
financial objectives, which we believe are core to Biogen’s next
chapter of biotech leadership and our ability to create attractive
returns for our shareholders.”
Before joining Biogen, Ms. Kramer held senior finance roles at
Hertz Global Holdings, Inc., Fisher Scientific International, Inc.
and The Gillette Company, and was an audit partner at Deloitte
& Touche LLP, Ernst & Young LLP and Arthur Andersen LLP.
Ms. Kramer currently serves as Chair of the Board of Directors and
Audit Committee of Armata Pharmaceuticals and serves on the Board
of Directors and Finance Committee of the Center for Women and
Enterprise. She holds a B.S.B.A. in Accounting from Salem State
University and is a licensed CPA in the Commonwealth of
Massachusetts.
“I am deeply grateful for my time at Biogen and for the
company’s unwavering commitment to patients, which has profoundly
impacted me. It has truly been a privilege serving as Biogen's
Chief Financial Officer," said Mike McDonnell. "While I look
forward to retirement and the opportunity to spend more time with
my family, who have supported me throughout my career, I will miss
working alongside my exceptional colleagues. I'm especially
grateful to Robin Kramer for her partnership and congratulate her
on her appointment as Biogen’s next CFO; I am confident she will
excel in this role.”
About BiogenFounded in 1978, Biogen is a
leading biotechnology company that pioneers innovative science to
deliver new medicines to transform patients’ lives and to create
value for shareholders and our communities. We apply deep
understanding of human biology and leverage different modalities to
advance first-in-class treatments or therapies that deliver
superior outcomes. Our approach is to take bold risks, balanced
with return on investment to deliver long-term growth.
We routinely post information that may be important to investors
on our website at www.biogen.com. Follow us on social
media - Twitter, LinkedIn, Facebook, YouTube.
Biogen Safe Harbor This news release
contains forward-looking statements, including regarding the
potential of Biogen's commercial business and pipeline programs;
the anticipated benefits and potential of investments, optimization
of our cost structure, Biogen’s future strategic and financial
results. These statements may be identified by words such as "aim,"
"anticipate," "believe," "could," "estimate," "expect," "forecast,"
"intend," "may," "plan," "possible," "potential," "will," "would"
and other words and terms of similar meaning. Drug development and
commercialization involve a high degree of risk, and only a small
number of research and development programs result in
commercialization of a product. Results in early-stage clinical
studies may not be indicative of full results or results from later
stage or larger scale clinical studies and do not ensure regulatory
approval. You should not place undue reliance on these
statements.These statements involve risks and uncertainties that
could cause actual results to differ materially from those
reflected in such statements, including without limitation
unexpected concerns that may arise from additional data, analysis
or results obtained during clinical studies; the occurrence of
adverse safety events; risks of unexpected costs or delays; the
risk of other unexpected hurdles; regulatory submissions may take
longer or be more difficult to complete than expected; regulatory
authorities may require additional information or further studies,
or may fail or refuse to approve or may delay approval of Biogen's
drug candidates; actual timing and content of submissions to and
decisions made by the regulatory authorities regarding our products
or product candidates; uncertainty of success in the development
and potential commercialization of the medicine; failure to protect
and enforce Biogen's data, intellectual property and other
proprietary rights and uncertainties relating to intellectual
property claims and challenges; product liability claims; and third
party collaboration risks, results of operations and financial
condition. The foregoing sets forth many, but not all, of the
factors that could cause actual results to differ from Biogen's
expectations in any forward-looking statement. Investors should
consider this cautionary statement as well as the risk factors
identified in Biogen's most recent annual or quarterly report and
in other reports Biogen has filed with the U.S. Securities and
Exchange Commission. These statements speak only as of the date of
this news release. Biogen does not undertake any obligation to
publicly update any forward-looking statements.
MEDIA
CONTACT:BiogenJack Cox+ 1 781 464
3260public.affairs@biogen.com |
INVESTOR
CONTACT:BiogenStephen Amato+1 781 464
2442IR@biogen.com |
Biogen (NASDAQ:BIIB)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Biogen (NASDAQ:BIIB)
Historical Stock Chart
Von Dez 2023 bis Dez 2024